Effects of Antihypertensive Treatment in HIV Infected Patients: Candesartan Versus Lercanidipine

The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2007 by Università degli Studi dell'Insubria.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Università degli Studi dell'Insubria
ClinicalTrials.gov Identifier:
NCT00564057
First received: November 26, 2007
Last updated: December 5, 2007
Last verified: November 2007

November 26, 2007
December 5, 2007
September 2007
Not Provided
  • morpho-functional left ventricle characteristics [ Time Frame: one year ]
  • metabolic profile [ Time Frame: one year ]
Same as current
Complete list of historical versions of study NCT00564057 on ClinicalTrials.gov Archive Site
systolic and diastolic blood pressure [ Time Frame: one year ]
Same as current
Not Provided
Not Provided
 
Effects of Antihypertensive Treatment in HIV Infected Patients: Candesartan Versus Lercanidipine
Effects of Antihypertensive Treatment on Cardiac Remodelling and Metabolic Profile in HIV Infected Patients: Randomized Longitudinal Study With Candesartan Versus Lercanidipine

Human immunodeficiency virus infection and highly active antiretroviral therapy (HAART) are associated with an increased risk of cardiovascular disease: a wide range of alterations in lipid and glucose metabolism has been increasingly recognized in HIV patients treated with HAART. Few data are available on the effects of antihypertensive treatment on cardiac morpho-functional characteristics and metabolic parameters in HIV patients. Aim of the study is to assess the effects of chronic therapy with angiotensin receptor blocker(candesartan)or calcium channel blocker (lercanidipine)on metabolic profile and cardiac remodelling in HIV hypertensive patients.

Not Provided
Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
  • HIV Infections
  • Hypertension
  • Drug: candesartan
    tablet 8-16 mg once daily, one year
  • Drug: lercanidipine
    tablets 10-20 mg once daily, one year
  • Experimental: 1
    candesartan 8-16 mg once daily
    Intervention: Drug: candesartan
  • Active Comparator: 2
    lercanidipine 10-20 mg once daily
    Intervention: Drug: lercanidipine

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
30
September 2009
Not Provided

Inclusion Criteria:

  • HIV infection
  • office blood pressure > 140/90 mmHg
  • no antihypertensive treatment
  • good quality echocardiogram

Exclusion Criteria:

  • cardiovascular diseases
  • hypothyroidism
  • diabetes
  • secondary hypertension
  • hepatic and renal failure
Both
18 Years to 65 Years
No
Contact: anna maria grandi, MD +39 0332 278403 amgrandi@libero.it
Italy
 
NCT00564057
44758
No
Not Provided
Università degli Studi dell'Insubria
Not Provided
Study Chair: anna maria grandi, MD University of Insubria, Varese, ITALY
Principal Investigator: paolo grossi, MD University of Insubria, Varese, Italy
Principal Investigator: andrea maria maresca, MD University of Insubria, Varese, Italy
Principal Investigator: eleonora nicolini, MD University of Insubria, Varese, Italy
Principal Investigator: massimo giola, MD University of Insubria, Varese, Italy
Università degli Studi dell'Insubria
November 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP